These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38233885)

  • 41. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study.
    Hahn AF; Bolton CF; Zochodne D; Feasby TE
    Brain; 1996 Aug; 119 ( Pt 4)():1067-77. PubMed ID: 8813271
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of intravenous immunoglobulin (IVIG) treatment on patients with dermatomyositis: a 4-year follow-up study.
    Kampylafka EI; Kosmidis ML; Panagiotakos DB; Dalakas M; Moutsopoulos HM; Tzioufas AG
    Clin Exp Rheumatol; 2012; 30(3):397-401. PubMed ID: 22510247
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial.
    Hanna MG; Badrising UA; Benveniste O; Lloyd TE; Needham M; Chinoy H; Aoki M; Machado PM; Liang C; Reardon KA; de Visser M; Ascherman DP; Barohn RJ; Dimachkie MM; Miller JAL; Kissel JT; Oskarsson B; Joyce NC; Van den Bergh P; Baets J; De Bleecker JL; Karam C; David WS; Mirabella M; Nations SP; Jung HH; Pegoraro E; Maggi L; Rodolico C; Filosto M; Shaibani AI; Sivakumar K; Goyal NA; Mori-Yoshimura M; Yamashita S; Suzuki N; Katsuno M; Murata K; Nodera H; Nishino I; Romano CD; Williams VSL; Vissing J; Auberson LZ; Wu M; de Vera A; Papanicolaou DA; Amato AA;
    Lancet Neurol; 2019 Sep; 18(9):834-844. PubMed ID: 31397289
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma.
    Chapel HM; Lee M; Hargreaves R; Pamphilon DH; Prentice AG
    Lancet; 1994 Apr; 343(8905):1059-63. PubMed ID: 7909099
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study.
    Dalakas MC; Sonies B; Dambrosia J; Sekul E; Cupler E; Sivakumar K
    Neurology; 1997 Mar; 48(3):712-6. PubMed ID: 9065553
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Intravenously-administered immunoglobulins as first-choice agent in juvenile dermatomyositis].
    Breems DA; de Haas PW; Visscher F; Sabbe LJ; Busch HF; van Doorn PA
    Ned Tijdschr Geneeskd; 1993 Sep; 137(39):1979-82. PubMed ID: 8413708
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 49. IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status.
    Illa I
    J Neurol; 2005 May; 252 Suppl 1():I14-8. PubMed ID: 15959667
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study.
    Dauvilliers Y; Arnulf I; Foldvary-Schaefer N; Morse AM; Šonka K; Thorpy MJ; Mignot E; Chandler P; Parvataneni R; Black J; Sterkel A; Chen D; Skobieranda F; Bogan RK
    Lancet Neurol; 2022 Jan; 21(1):53-65. PubMed ID: 34942138
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial.
    Mazeraud A; Jamme M; Mancusi RL; Latroche C; Megarbane B; Siami S; Zarka J; Moneger G; Santoli F; Argaud L; Chillet P; Muller G; Bruel C; Asfar P; Beloncle F; Reignier J; Vinsonneau C; Schimpf C; Amour J; Goulenok C; Lemaitre C; Rohaut B; Mateu P; De Rudnicki S; Mourvillier B; Declercq PL; Schwebel C; Stoclin A; Garnier M; Madeux B; Gaudry S; Bailly K; Lamer C; Aegerter P; Rieu C; Sylla K; Lucas B; Sharshar T
    Lancet Respir Med; 2022 Feb; 10(2):158-166. PubMed ID: 34774185
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-Term Safety and Tolerability During a Clinical Trial and Open-Label Extension of Low-Sodium Oxybate in Participants with Narcolepsy with Cataplexy.
    Bogan RK; Foldvary-Schaefer N; Skowronski R; Chen A; Thorpy MJ
    CNS Drugs; 2023 Apr; 37(4):323-335. PubMed ID: 36947322
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies.
    Barbasso Helmers S; Dastmalchi M; Alexanderson H; Nennesmo I; Esbjörnsson M; Lindvall B; Lundberg IE
    Ann Rheum Dis; 2007 Oct; 66(10):1276-83. PubMed ID: 17277004
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content.
    Manlhiot C; Tyrrell PN; Liang L; Atkinson AR; Lau W; Feldman BM
    Pediatrics; 2008 Mar; 121(3):e626-30. PubMed ID: 18299304
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Acute stroke with high-dose intravenous immune globulin.
    White DA; Leonard MC
    Am J Health Syst Pharm; 2007 Aug; 64(15):1611-4. PubMed ID: 17646563
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Low-dose intravenous immunoglobulin treatment for complex regional pain syndrome (LIPS): study protocol for a randomized controlled trial.
    Goebel A; Shenker N; Padfield N; Shoukrey K; McCabe C; Serpell M; Sanders M; Murphy C; Ejibe A; Milligan H; Kelly J; Ambler G
    Trials; 2014 Oct; 15():404. PubMed ID: 25344328
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.
    Ramanan AV; Quartier P; Okamoto N; Foeldvari I; Spindler A; Fingerhutová Š; Antón J; Wang Z; Meszaros G; Araújo J; Liao R; Keller S; Brunner HI; Ruperto N; ;
    Lancet; 2023 Aug; 402(10401):555-570. PubMed ID: 37423231
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The therapeutic efficacy and safety of intravenous immunoglobulin in dermatomyositis and polymyositis: A systematic review and meta-analysis.
    Xiong A; Qiang Y; Cao Y; Shuai Y; Chen H; Xiang Q; Hu Z; Song Z; Zhou S; Zhang Y; Cui H; Wang Y; Luo J; Shuai S; Yang Y
    Mod Rheumatol; 2023 Apr; 33(3):533-542. PubMed ID: 35660927
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hyperimmune anti-COVID-19 IVIG (C-IVIG) Therapy for Passive Immunization of Severe and Critically Ill COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial.
    Ali S; Luxmi S; Anjum F; Muhaymin SM; Uddin SM; Ali A; Ali MR; Tauheed S; Khan M; Bajwa M; Baig SU; Shalim E; Ahmed I; Khan AS; Quraishy S
    Trials; 2020 Nov; 21(1):905. PubMed ID: 33138867
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intravenous immunoglobulin for hypogammaglobulinemia after lung transplantation: a randomized crossover trial.
    Lederer DJ; Philip N; Rybak D; Arcasoy SM; Kawut SM
    PLoS One; 2014; 9(8):e103908. PubMed ID: 25090414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.